ABSTRACT The efficacy and safety of a 3 hr, 80 mg intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) were investigated in 47 patients with acute myocardial infarction. Coronary angiography, performed before the administration of rt-PA and for 90 min thereafter, demonstrated that 37 patients had total coronary occlusion before therapy. After 90 min of rt-PA (50 mg), reperfusion of the infarct-related artery was observed in 25 patients (68%). 
THERAPY AND PREVENTION-CORONARY THROMBOLYSIS thrombolytic agents such as streptokinase or urinokinase because of the formation in plasma of plasmin from circulating plasminogen. Consumption of a2-antiplasmin is followed by increased circulating plasmin with subsequent proteolysis of numerous plasma proteins required for normal hemostasis. However, certain recently discovered plasminogen activators appear to be more specific for plasminogen when bound to fibrin.9t" The theoretical advantage of fibrin specific activation is that systemic lytic states may be avoided, thus reducing the potential for serious bleeding. One of these activators, recombinant tissue-type plasminogen activator (rt-PA), has been isolated and produced by recombinant DNA techniques. 12 To determine whether thrombolytic therapy favorably effects outcome in patients with AMI, the National Heart, Lung, and Blood Institute established a multicenter trial, the Thrombolysis in Myocardial Infarction Trial (TIMI). Selecting the optimal thrombolytic agent to be compared against placebo was an early objective of this trial. Although substantial data are available regarding the use of streptokinase in AMI, only one investigation had previously assessed the ability of intravenous rt-PA to recanalize patients with AMI. '3 Rt-PA was administered in varying doses (0.25 to 0.75 mg/kg) for varying durations (30 to 120 min). A dose of 0.75 mg/kg administered over 120 min to 15 patients resulted in the highest reperfusion rate (87%). Modest declines in fibrinogen concentration were observed at 90 min after rt-PA therapy; reocclusion was observed in 20% of patients within 30 min after cessation of the rt-PA infusion.
Based on these initial observations, rt-PA appeared to be a potential activator for use in the TIMI trial. To be selected as the agent of choice, however, additional important questions needed to be addressed. First, would the effects of rt-PA be similar when administered as a single, fixed dosage regimen to a larger cohort of patients derived from multiple clinical sites with data analyzed by central laboratories? Second, could the incidence of reocclusion be decreased if the rt-PA infusion was prolonged and continuous anticoagulation with heparin was added? Third, would a greater dose of rt-PA have more pronounced effects on fibrinogenolysis? To address these questions, TIMI investigators performed an open-label trial of intravenous rt-PA. rt-PA was administered as a 3 hr infusion, 40 mg for the first hour and 20 mg for each of the 2 subsequent hours, to 47 patients with AMI. The results of this trial, reported herein, formed the basis for selecting this dosage regimen of rt-PA in a subsequent blinded, direct comparison of the safety and efficacy of intravenous rt-PA vs that of intravenous streptokinase. 14 Methods Study population. To be eligible for recruitment, patients had to satisfy the following inclusion criteria: (1) age less than 76 years, (2) chest pain characteristic of myocardial ischemia for at least 30 min, (3) electrocardiographic ST segment elevation of at least 0.1 mV in at least two leads reflecting a single myocardial region (Q waves were not a contraindication), (4) elapsed time from onset of ischemic pain to recruitment less than 7 hr, and (5) angiographically documented obstruction (greater than 50% diameter reduction) of the coronary artery supplying the infarct zone. Patients were excluded for the following reasons: (1) shock despite vasopressor therapy, (2) agitation or lethargy such that informed consent could not be obtained, (3) child-bearing potential, (4) past or present bleeding disorder or significant gastrointestinal bleeding, (5) anticoagulation therapy, (6) left bundle branch block, (7) prosthetic heart valve, (8) dilated cardiomyopathy, (9) other serious advanced illnesses, such as cancer, (10) uncontrolled hypertension (diastolic pressure greater than 120 mm Hg), (1 1) significant surgical procedure within last 2 weeks, (12) previous participation in this trial, (13) prolonged cardiopulmonary resuscitation within the last 2 weeks, (14) psychological or physical inability to participate, (15) cerebral vascular accident within the last 6 months, (16) previous coronary artery bypass surgery, or (17) severe trauma within the last 6 months.
Study design. After obtaining informed consent, patients meeting all eligibility criteria were taken to the cardiac catheterization laboratory. An intravenous bolus of heparin (100 units/ kg USP) was administered after access to the systemic venous and arterial circulations was obtained. Left ventricular and systemic arterial pressures were recorded. Contrast left ventriculography was performed in the right anterior oblique projection.
The coronary arterial system remote from the infarct zone was visualized first, followed by coronary cineangiographic examination of the vessel supplying the infarct zone. Angiographic projections were standardized among clinical sites. Patients not demonstrating significant obstruction (less than 50% reduction in luminal diameter) of the coronary artery supplying the infarct zone did not receive rt-PA. For those patients with significant obstruction 200 gg nitroglycerin was injected selectively into the infarct-related artery. If obstruction persisted, rt-PA was infused intravenously at a dosage of 40 mg/hr for 1 hr followed by 20 mg/hr for 2 hr (total dose 80 mg over 3 hr). Coronary cineangiography of the infarct-related artery was repeated at 10, 20, 30, 45, 60, 75, and 90 assessed by the radiographic core laboratory. Qualitative analysis of the coronary cineangiograms included classification of the degree of perfusion of the infarct-related artery. The following grading system was used: grade 0, no perfusion (absence of contrast beyond the point of occlusion); grade 1, penetration of the thrombus with minimal perfusion (contrast material passes beyond the area of obstruction but fails to opacify the distal coronary bed and is not cleared during the course of the cine run); grade 2, partial perfusion (the contrast material passes through the obstruction and opacifies the coronary bed distal to the obstruction and the rate of entry of contrast into the distal vessel and its clearance are slower than that of nonstenosed vessels); grade 3, complete perfusion (contrast material promptly enters the coronary artery distal to the obstruction and clears at a rate similar to that in nonstenosed coronary vessels). Based on the grading system, total coronary occlusion was considered to be present when perfusion was grade 0 or grade 1. Reperfusion of a totally occluded coronary artery was defined as an improvement to grade 2 or grade 3. Additional quantitative analysis of the obstruction in the infarct-related artery included, when technically possible, measurement of percent diameter reduction with the use of a computerized edge-detection technique. 15 Measurements were made before treatment, at 90 minm and during the second catheterization procedure. Left ventricular cineangiograms were also analyzed by the radiographic core laboratory. Projected cine images were traced and digitized. End-diastolic and end-systolic volumes were determined and ejection fraction was calculated. 16 Statistical design of the study and data collection and management and analysis of results were performed by the data coordinating center. rt-PA was supplied by Genentech Laboratories. rt-PA was packaged, labeled, and shipped to clinical centers by the drug distribution center. A coagulation core laboratory was established to assess the changes in plasma levels of fibrinogen, plasminogen, and fibrin(ogen) degradation products. Blood samples for these measurements were collected before, immediately after, and 24 hr after the infusion of rt-PA.
Because of the presence of heparin in the blood samples. fibrinogen levels were measured by the method of Martinek and Berry`7 in citrated plasma prepared from blood collected into tubes containing 250 ,u/ml of aprotonin (Trasylol, FBA Pharmaceuticals, New York). Plasma plasminogen activity was measured in citrated plasma by the method of Friberger and Knos 8 with the use of a chromogenic substrate, S-2251 (Kabi Diagnostica, Stockholm, Sweden). The results are expressed as percent of activity in relation to that in pooled normal plasma taken as 100%. The levels of fibrin(ogen) degradation products were measured in serum harvested from blood (2 ml) collected into tubes containing thrombin (20 NIH units) , soybean trypsin inhibitor (3670 NF units), and protamine sulfate (50 ,g, Eli Lily
Company, Indianapolis). The Thrombo-Wellcotest method was employed using latex particles coated with antibodies against fibrinogen fragments D and E (Wellcome Diagnostics, Temple Hill, Dartford, England).
All deaths and episodes of significant bleeding were reviewed by a mortality and morbidity committee. Bleeding episodes were reviewed if they were associated with any of the following: (1) a reduction in heparin dosage, (2) a decline in hemoglobin of 3 g/dl, (3) transfusion of blood cells, clotting factors, or platelets, (4) intracranial or gastrointestinal bleeding, or (5) the administration of drugs to reverse thrombolytic or anticoagulant effects. After review, bleeding episodes were classified as major, minor, or not significant. Bleeding was judged to be major if hemoglobin declined more than 5 g/dl or if bleeding was intracranial. Bleeding episodes were considered to be minor if blood loss (1) was observed and hemoglobin declined more than 3 but less than 5 g/dl or (2) 
Results
Fifty-one eligible patients consented to participate in this trial. Four did not receive rt-PA because a catheterization lab was not available (n = 2) or less than a 50% stenosis was observed in the infarct-related artery (n = 2). Thus, 47 patients with AMI received intravenous rt-PA. Thirty-two of the patients were men. The age ranged from 34 to 74, with a mean age of 57 years. The infarct-related artery was the left anterior descending in 25 patients (53%), the right coronary in 20 patients (43%), and the left circumflex in two patients (4%). No patient had myocardial infarction attributed to left main coronary occlusion. Nineteen patients (40%) had single-vessel disease. The elapsed time from the onset of symptoms to the initiation of thrombolytic therapy ranged from 66 to 477, with the mean of 289 minutes. Left ventricular ejection fraction ranged from 21% to 79%; the value for the group was 47.6 ± 12.5% (mean + SD).
Thirty-eight patients (81%) had total occlusion of the infarct-related artery at the time of the initial angiogram (figure 1). After intracoronary nitroglycerin, one of these patients demonstrated reperfusion and thus 37 patients had total occlusion at the outset of rt-PA therapy. During the 90 min of angiographic observation, while rt-PA was being infused, 29 of these patients (78%) demonstrated reperfusion. Reperfusion was transient in four of these patients who developed reocclusion during the period of observation. Thus, at the final 90 min angiogram, reperfusion during rt-PA therapy was observed in 25 (68%) of the 37 patients who presented with total coronary occlusion. The degree of stenosis in the reperfused arteries ranged from 69% to 93% and averaged 84 ± 7%. The elapsed time from the initiation of rt-PA therapy to reperfusion ranged from 10 to 90 and averaged 40 + 25 min, with a median time of 30 min.
If patients with total occlusion were alternatively defined as those with grade 0 perfusion, reperfusion rates were similar to those described above. Hence, of the 27 patients who exhibited grade 0 perfusion after receiving intracoronary nitroglycerin, 20 (74%) demonstrated reperfusion during the period of observation, with 18 (67%) remaining grade 2 or 3 at 90 min.
Ten patients demonstrated subtotal occlusion of the infarct-related coronary artery before rt-PA therapy. bleeding complication (n = 1), or proximal left coronary dissection at the time of the initial procedure (n = 1 with uneventful hospital course). In 33 patients, the follow-up catheterization was done just before hospital discharge. In the other three, catheterization was done earlier (1 to 2 days after rt-PA therapy) because of recurrent ischemia. Of the 25 patients who had initially presented with total occlusion and experienced reperfusion at 90 min, 21 underwent follow-up angiography. The infarct-related artery demonstrated sustained perfusion in 14 or two-thirds of this subset. In 12 patients reperfusion was not demonstrated at 90 minutes. Six of these patients underwent follow-up angiography. Late reperfusion was observed in four or two thirds of those who were studied. Thus, although a high proportion of patients presenting with total occlusion demonstrated reperfusion during rt-PA infusion, one-third of the reperfused patients who were restudied developed reocclusion during the period of anticoagulation with heparin. Of patients who did not demonstrate reperfusion during the initial catheterization, two-thirds did so later.
Of the 10 patients who had subtotal occlusion before receiving rt-PA therapy, follow-up angiography was obtained in nine. decline (-29 ± 16%) was observed in fibrinogen and plasminogen (-59 + 18%) concentrations while fibrin(ogen) degradation products rose. In no patient did the fibrinogen levels decline to less than 140 mg/dl. At 24 hr after intravenous rt-PA, values of fibrinogen and plasminogen increased, but were still significantly different from baseline values. At 24 hr, the concentration of fibrin(ogen) degradation products was not different than that at baseline.
Discussion
The objective of this trial was to assess the efficacy and safety of a new thrombolytic activator, rt-PA, administered as a 3 hr, 80 mg continuous infusion. Although rt-PA was given intravenously, each patient underwent cardiac catheterization, including coronary cineangiography, before and during the rt-PA infusion. Coronary cineangiographic examinations provided: (1) confirmation of significant obstructive coronary artery disease and identification of the infarct-related artery, (2) a determination of whether the infarct-related artery was either totally or subtotally occluded, and (3) an objective and accurate means of determining reperfusion.
The primary end point in this investigation was re- The 33% reocclusion rate observed after intravenous rt-PA in this trial exceeds that reported after intravenous (10% to 24%) or intracoronary (17%) streptokinase.7, [20] [21] [22] Since intravenous streptokinase causes a prolonged systemic "lytic state" associated with depletion of clotting factors and reduction in blood viscosity, coronary reocclusion may be less common after streptokinase than after agents demonstrating fibrin specificity. Results of the randomized phase I TIMI trial, which compared rt-PA and streptokinase, will address this issue. On the other hand, factors unrelated to characteristics of thrombolytic agents, such as the severity of the underlying atherosclerotic coronary stenosis, may be of greater importance in contributing to reocclusion.23 Use of coronary angioplasty subsequent to thrombolytic therapy to further relieve coronary obstruction24 needs to be considered and will be evaluated in forthcoming phases of the TIMI trial.
In contrast to patients with totally occluded infarct- After treatment with rt-PA, significant decreases were noted in plasma levels of fibrinogen (-296%) and plasminogen (-59%) that were associated with an increase in fibrin(ogen) degradation products. These findings indicate that, at the dosage used, rt-PA induced some degree of systemic fibrinogenolysis. The magnitude of this effect, however, appears to be less than that reported with streptokinase.'
Bleeding was the most common complication in this trial; most of the episodes of bleeding were classified as major and required blood transfusion. However, it must be noted that each patient was fully anticoagulated with heparin immediately before and after the administration of rt-PA and each patient underwent an invasive vascular procedure immediately before the administration of rt-PA. In all but two instances of major bleeding, the primary source of bleeding was at the vascular entry site used for the catheterization procedure. Thus, a significant proportion of patients who receive rt-PA and heparin may demonstrate bleeding if cardiac catheterization is performed. Since serious episodes of bleeding at sites other than that of catheterization were infrequent (two in 47 patients), and since the observed declines in fibrinogen were not extreme in magnitude, if rt-PA were administered alone and without initial catheterization, one would expect that instances of major bleeding would be infrequent.
Recurrent myocardial infarction was observed in 15% (7/47) of the patients in this trial. With the exception of two patients, reinfarction occurred among patients who initially presented with total occlusion and demonstrated reperfusion at 90 min. The occurrence of reinfarction was distributed over the week after the qualifying AMI. Of patients who might have been expected to benefit the most from thrombolytic therapy, i.e., those with total occlusion and early reperfusion, the incidence of subsequent reinfarction was 20%. Initial angiographic examinations indicated that reinfarction was highly predictive of reocclusion of the 344 CIRCULATION infarct-related artery. Thus, although a brief intravenous infusion of rt-PA is capable of promoting reperfusion in a high proportion of patients with AMI and total coronary obstruction, for some patients, efforts in addition to anticoagulation with heparin will be required to sustain this salutary effect.
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